Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Teclistamab
Related studies linked through entity extraction aliases.
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE3
Teclistamab-Daratumumab in AL Amyloidosis
- Status
- RECRUITING
- Phase
- PHASE2
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1
A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE4
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
- Status
- RECRUITING
- Phase
- PHASE2
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
The Norwegian Immunotherapy in Multiple Myeloma Study
- Status
- RECRUITING
- Phase
- N/A
A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
- Status
- RECRUITING
- Phase
- PHASE2
ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
- Status
- RECRUITING
- Phase
- PHASE2
Study on the Clinical Efficacy of Teclistamab
- Status
- RECRUITING
- Phase
- N/A
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1